Financhill
Back

Blueprint Medicines Quote, Financials, Valuation and Earnings

Blueprint Medicines Price Quote

$94.25
+0.10 (+-2.45%)
(Updated: November 23, 2024 at 4:34 AM ET)

Blueprint Medicines Key Stats

Sell
37
Blueprint Medicines (BPMC) is a Sell

Day range:
$94.11 - $98.34
52-week range:
$66.61 - $121.90
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.60
P/B ratio:
19.1%

Volume:
663.5K
Avg. volume:
687.7K
1-year change:
40.5%
Market cap:
$6B
Revenue:
$249.4M
EPS:
$-2.11

How Much Does Blueprint Medicines Make?

Is Blueprint Medicines Growing As A Company?

  • What Is Blueprint Medicines's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 1.27%
  • What Is Blueprint Medicines's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Blueprint Medicines Stock Price Performance

What Is Blueprint Medicines 52-Week High & Low?

Blueprint Medicines Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Blueprint Medicines?

Is Blueprint Medicines Cash Flow Positive?

  • What Is BPMC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$242.2M
  • What Is Blueprint Medicines’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $278.9M
  • What Is Blueprint Medicines’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.4M

Blueprint Medicines Return On Invested Capital

  • Is Management Doing A Good Job?
    BPMC return on invested capital is -23.14%
  • What Is Blueprint Medicines Return On Assets?
    ROA measures how assets are converting to revenues and is -11.44%
  • What Is BPMC Return On Equity?
    ROE is a measure of profitability and is -50.13%

Blueprint Medicines Earnings Date & Stock Price

Blueprint Medicines Competitors

  • Who Are Blueprint Medicines's Competitors?
    Below is a list of companies who compete with Blueprint Medicines or are related in some way:
    • Biomarin Pharmaceutical Inc (BMRN)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Regeneron Pharmaceuticals Inc (REGN)

Blueprint Medicines Dividend Yield

Blueprint Medicines Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 7.41%
Revenue: 126.61% 0.56%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 5
Sell Recommendations: 1
Price Target: 125.58
Upside from Last Price: 33.38%

Major Shareholders

  • How many BPMC shares are owned by institutional investors?
    113.2M BPMC shares are owned by institutional investors
  • How many BPMC shares are owned by insiders?
    1.4M BPMC shares are owned by insiders